A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors

Abstract Inhibiting the aggregation of Amyloid β (1-42) is a promising strategy for the development of disease-modifying Alzheimer’s disease therapeutics. To date, however, no sufficiently efficacious inhibitors have been identified, despite the best efforts of more than 200 advanced drug development campaigns. This failure can be partially attributed to limitations in current in vitro compound screening and in vivo validation assays. Here, we report a high throughput assay platform based on the use of a fluorescence lifetime aggregation sensor that can be applied in vitro and in vivo. This microfluidic “nanoFLIM” assay presents a cost-effective and reliable alternative to conventional early-stage small molecule discovery platforms for cell-free Amyloid β aggregation. The fluorescence lifetime sensor can dynamically monitor peptide aggregation in cellular and Caenorhabditis elegans disease models, providing directly comparable aggregation kinetics, which is not achievable by any other method. The power of this unified platform for accelerating hit-to-lead strategies, lowering attrition rates and expediting in vivo screening, was demonstrated with a pilot screening campaign of 445 compounds, revealing an inhibitor that can inhibit Amyloid β self-assembly both in vitro as well as in cellular and whole organism disease models.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-13
DOI
https://doi.org/10.1038/s41467-026-78202-8
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors

Clemens F. Kaminski, Gianluigi Veglia, Súil Collins, Liisa van Vliet et al.
Nature Communications
Alzheimer's disease research and treatments
article

A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors

Clemens F. Kaminski, Gianluigi Veglia, Súil Collins, Liisa van Vliet, Fabrice Gielen, Giuliana Fusco, Florian Hollfelder, Nino F. Läubli, Gabriele S. Kaminski Schierle, Tomáš Deingruber, David R. Spring, Ana Fernández‐Villegas, M. Janecek, Chetan Poudel, Claire Michel, Sara Wagner Valladolid
article en

Abstract

Abstract Inhibiting the aggregation of Amyloid β (1-42) is a promising strategy for the development of disease-modifying Alzheimer’s disease therapeutics. To date, however, no sufficiently efficacious inhibitors have been identified, despite the best efforts of more than 200 advanced drug development campaigns. This failure can be partially attributed to limitations in current in vitro compound screening and in vivo validation assays. Here, we report a high throughput assay platform based on the use of a fluorescence lifetime aggregation sensor that can be applied in vitro and in vivo. This microfluidic “nanoFLIM” assay presents a cost-effective and reliable alternative to conventional early-stage small molecule discovery platforms for cell-free Amyloid β aggregation. The fluorescence lifetime sensor can dynamically monitor peptide aggregation in cellular and Caenorhabditis elegans disease models, providing directly comparable aggregation kinetics, which is not achievable by any other method. The power of this unified platform for accelerating hit-to-lead strategies, lowering attrition rates and expediting in vivo screening, was demonstrated with a pilot screening campaign of 445 compounds, revealing an inhibitor that can inhibit Amyloid β self-assembly both in vitro as well as in cellular and whole organism disease models.

Nature Communications
University of Exeter (GB), University of Cambridge (GB), Imperial College London (GB)
Wellcome Trust, Cambridge Trust, Directorate for Biological Sciences, Horizon 2020 Framework Programme, Medical Research Council, Biotechnology and Biological Sciences Research Council
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon